Two drugs not worth the price for certain breast cancer patients
Feb 14, 2012
A new report by the National Institute for Health and Clinical Excellence (Nice) explained that the use of two drugs, Tyverb and Herceptin, for breast cancer patients with a specific form of the cancer is not advisable because they are simply too expensive, according to The Telegraph.
The drugs have been known for reduce tumors, however the amount is not worth how much the drugs actually cost.
"Having reviewed the available evidence, our committee of experts has found that while both lapatinib and trastuzumab can reduce the growth and further spread of metastatic breast cancer tumors when taken alongside the aromatase inhibitors letrozole and anastrozole, the extent that these treatments can improve overall survival appears to be small or undefined," Sir Andrew Dillon, the chief executive of Nice told the news source.
According to the American Cancer Society, one in eight women in the U.S. will be diagnosed with breast cancer at some point during her lifetime. It is recommended that once a woman turns 40, she schedules an annual mammogram. This way, women are able to ensure they do not have the disease, and if they do, they detect it early.